Sort
10,766 grants matching “checkpoint inhibitor”
Towards targeting the lymphoma microenvironment
$908,577Hans-Guido Wendel · Sloan-Kettering Inst Can Research · R35 · FY2023 · CA
Vaccine and Drug Combination Therapy for Human Cancers
$908,412James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Mechanisms of Cellular Transformation by HTLV-1
$907,824Kuan-Teh Jeang · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
CD180 targeted immunotherapeutic for chronic HBV in HIV infected patients
$907,661Deborah L. Fuller · University Of Washington · R56 · FY2019 · AI
OVERCOMING KIDNEY CANCER RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS
$907,227The University Of Texas Southwestern Medical Center · · FY2020 · Defense Health Agency
Cancer immunotherapy
$906,886Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Optimizing AAV delivery of bNAbs for HIV prevention
$906,720Matthew Ryan Gardner · Emory University · R01 · FY2022 · AI
Live cell reporters of genetic changes in stiff vs soft surroundings - Causes & Consequences
$904,567Dennis E. Discher · University Of Pennsylvania · U01 · FY2022 · CA
Synthetic metabolism to armor and enhance a new class of cell therapies
$904,385John James Blazeck · Georgia Institute Of Technology · DP2 · FY2025 · CA
Cancer Immunotherapy Clinical Trials
$902,872Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$901,309Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2022 · CA
Effect of tumor editing on antitumor immunity
$901,205Judy Lieberman · Boston Children'S Hospital · R35 · FY2025 · CA
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
$899,708William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA
Project 1: Transgenic TCR-mediated tumor therapy
$899,284Philip D Greenberg · University Of Washington · P01 · FY2022 · CA
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2018 · CA
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2020 · CA
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2021 · CA
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2016 · CA
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2017 · CA
SPORE in Bladder Cancer
$896,275Jonathan Eric Rosenberg · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA
Administrative Supplement: Interim Funding for Emory Lung Cancer SPORE
$896,274Suresh S Ramalingam · Emory University · P50 · FY2024 · CA
Immune selection of HIV-1 reservoir cells in human clinical trials
$895,990Mathias Lichterfeld · Brigham And Women'S Hospital · R01 · FY2024 · AI
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability
$895,633Christine A Iacobuzio-Donahue · Sloan-Kettering Inst Can Research · R35 · FY2021 · CA
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host
$894,960Ronald Levy · Stanford University · R35 · FY2018 · CA
Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas
$890,765George Yancey Gillespie · Treovir, Inc · R44 · FY2023 · CA